

ABSTRACT OF THE DISCLOSURE

Mucosal administration of OspA and compositions therefor are disclosed and claimed. More particularly, oral administration of OspA and compositions therefor for eliciting an immunological response against *Borrelia burgdorferi*, such as a protective response preventive of Lyme disease are disclosed and claimed. Thus, oral Lyme disease vaccines or immunological compositions and methods of use are disclosed and claimed.